Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VIR-5525 · AMX-525

Bispecific antibody · Immune activation, directed at epidermal growth factor receptor (EGFR) and CD3 (CD3E) · developed by Vir Biotechnology

Phase 1 Most advanced trial
VIR Developer
1 Registered trials

What is VIR-5525?

VIR-5525 (AMX-525) is a protease-activated, dual-masked T-cell engager with an EGFR-binding domain and a CD3-binding domain. Masking polypeptides are released by tumor protease cleavage in the tumor microenvironment, allowing it to bind T cells and EGFR-expressing tumor cells. It is being studied in EGFR-positive solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AMX-525
Drug type
Bispecific antibody
Targets
epidermal growth factor receptor (EGFR), CD3 (CD3E)
Mechanism
Immune activation, directed at epidermal growth factor receptor (EGFR) and CD3 (CD3E)
Pathways
T-cell mediated tumor cell killing
Therapy area
Oncology
Developer
Vir Biotechnology, Inc. (VIR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06960395 Phase 1 Solid Tumor Malignancies Recruiting VIR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

EGFREGFR Positive Solid TumorsSolid Tumor Malignancies

Other drugs acting on EGFR / CD3E

More from Vir Biotechnology

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.

Follow VIR, the company behind VIR-5525

See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VIR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.